An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Leuprorelin 10.72 mg implant) applied twice every 84 days
Latest Information Update: 19 Mar 2013
At a glance
- Drugs Leuprorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Feb 2013 Status changed from recruiting to completed as reported by EudraCT.
- 16 May 2012 New trial record